On April 11, 2022 Circle Pharma, a pre-clinical stage company focused ondeveloping macrocycle therapeutics against targets previously considered to be undruggable, reported that it will present a poster at theAmerican Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 8-13, in New Orleans, Louisiana (Press release, Circle Pharma, APR 11, 2022, View Source [SID1234611947]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s presentation will provide details of its progress towards structure-guided macrocycles that inhibit theprotein-protein interaction between the cyclin A:CDK2 complex and key substrates that are phosphorylated by thiscomplex. Inhibition of Cyclin A substrate binding has been postulated to be synthetic lethal in Rb mutated cancers. Thedata presented include evidence that macrocycle inhibitors of cyclin A induce G/M arrest and apoptosis in small cell lungcancer (SCLC) cell lines and have anti-tumor efficacy in SCLC xenograft animal models. Circle plans to advance its cyclinA inhibitor program to the clinic for testing in a range of cancer types, including SCLC where Rb mutations are highlyprevalent.

The presentation will be made as part of the Mechanisms of Drug Action / Experimental and Molecular Therapeuticssession at the AACR (Free AACR Whitepaper) meeting, Abstract No. 5379.